$12.850
-0.407 (-3.17%)收盤時
KLRA 同業比較
In the context of the broader market, KLRA competes directly with industry leaders such as KRSA and CMPS. With a market capitalization of $1.67B, it holds a leading position in the sector. When comparing efficiency, KLRA's gross margin of N/A stands against KRSA's N/A and CMPS's N/A. Such benchmarking helps identify whether Kailera Therapeutics Inc is trading at a premium or discount relative to its financial performance.
Kailera Therapeutics Inc 財務表現
Kailera has shown a significant increase in current assets, rising from 530,315,000 USD in Q1 2026 to 929,167,000 USD in Q2 2026, indicating improved liquidity. However, the company is still facing large net losses, with EPS reported at -1.09 for Q2 2026.
Financials
FY2026Q2
YoY:
+295.98%
-121.37M
Operating Profit
FY2026Q2
YoY:
+284.52%
-111.31M
Net Income after Tax
FY2026Q2
YoY:
+373.91%
-1.09
EPS - Diluted
FY2026Q2
YoY:
+195.55%
-77.53M
Free Cash Flow
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。